JDRF’s Mountain West Chapter hosted its Annual Meeting on June 23, sharing with attendees the remarkable progress made this past year in advancing type 1 diabetes (T1D) research.
Chaired by Colorado Community Board President Kim Higgins, and Utah Community Board President Chris German, the evening included a comprehensive overview of how JDRF gets therapies to the T1D community through funding discovery and translational research; advocating for timely regulatory approval of new treatments and therapies and comprehensive healthcare coverage; clinical adoption of those new treatments and therapies – and ultimately better outcomes for people with T1D.
The last fiscal year saw JDRF provide influence over $500 million in total research support, with most of that money focusing on cures. Disease-modifying therapies (including both Immune and Regenerative therapies); global universal screenings through T1Detect and Beta Cell Replacement therapies were just some of the highlights celebrated. Additionally, the continued development of better, smaller and less intrusive devices; better insulin; drugs for complications; and therapies for the psychosocial burden of T1D made significant contributions in improving the lives of those with T1D.
An overview of the role volunteers, donors and constituents in JDRF’s Mountain West Chapter played in supporting the mission revealed the chapter raised over $4.3 million dollars through JDRF One Walk; JDRF Hope Gala, JDRF Ride to Cure Diabetes; third party events; and the generosity of thousands of individual, corporate and foundation donors.
Learn more and watch the recording of the Mountain West Chapter Annual Meeting.